H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Asensus Surgical (ASXC – Research Report) today and set a price target of $2.00. The company’s shares closed yesterday at $0.33.
According to TipRanks, Ramakanth is an analyst with an average return of -20.5% and a 23.02% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Affimed, Vor Biopharma, and ImmunoGen.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Asensus Surgical with a $1.65 average price target.
See Insiders’ Hot Stocks on TipRanks >>
ASXC market cap is currently $78.59M and has a P/E ratio of -0.99.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TransEnterix, Inc. is a medical device company. It focuses on commercialization of Senhance System, that digitizes laparoscopic minimally invasive surgery. It offers the Senhance Surgical Robotic System, which offers robotic surgery for laparoscopic abdominal and pelvic surgery, as well as limited thoracic operations excluding cardiac and vascular surgery, and the SurgiBot System which refers to the a single-port, robotically enhanced laparoscopic surgical platform. The company was founded by William N. Starling in 2006 and is headquartered in Morrisville, NC.
Read More on ASXC:
- ASXC Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Asensus Surgical, Inc. Schedules Second Quarter Financial and Operating Results Conference Call for August 10, 2023
- Asensus Surgical trading resumes
- Asensus Surgical to sell 23.8M shares at 42c in registered direct offering
- Asensus Surgical Announces $10 Million Registered Direct Offering
